Loading
Loading
Organ & Bioregulator Research · 20mg
Janoshik-tested · 10 vials per kit
Cartalax is a synthetic tetrapeptide bioregulator studied in preclinical research for its effects on cartilage and joint tissue. Research has examined its potential to stimulate proteoglycan production, reduce cartilage matrix breakdown, protect chondrocyte density, and restore cartilage integrity. Studies have explored applications in osteoarthritis models, joint injury recovery, and sports rehabilitation.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Cartalax
Ala-Glu-Asp
Cartalax is a synthetic tripeptide (T-31, Ala-Glu-Asp) developed as a cartilage and connective tissue bioregulator in the Khavinson series. It targets musculoskeletal tissue maintenance, with research focused on chondrocyte regulation and extracellular matrix component synthesis.
Proposed to act via chromatin binding in chondrocytes and connective tissue cells, influencing gene expression related to extracellular matrix components including collagens, proteoglycans, and matrix metalloproteinase regulation. Anti-apoptotic effects on chondrocytes under inflammatory and oxidative stress conditions have been described.
Cartalax research includes models of cartilage degeneration, osteoarthritis, and age-related connective tissue decline. Combination with other structural bioregulators has been explored in musculoskeletal longevity protocols. Studies are predominantly from the Russian bioregulator research programme.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
